David McAllister

Title: The Innovations of David McAllister

Introduction

David McAllister is an accomplished inventor based in Notting Hill, Australia. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target viral infections.

Latest Patents

David McAllister holds 1 patent for his invention titled "Anhydrous crystalline free base form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole." This crystalline form is particularly useful in treating infections caused by Picornaviridae, such as the human rhinovirus (HRV). His patent also includes a method for manufacturing this free base crystalline form, which involves micronizing the compound particles and may utilize a wetting agent. Additionally, he has developed pharmaceutical compositions that incorporate this crystalline form, including tablets and suspensions, along with methods for therapeutic treatments.

Career Highlights

David McAllister is currently associated with Aviragen Therapeutics, Inc., where he continues to innovate in the pharmaceutical sector. His work focuses on creating effective treatments for viral infections, showcasing his commitment to advancing medical science.

Collaborations

David has collaborated with notable colleagues, including Edward Lee and Andrew Trigwell, to further enhance the impact of his research and inventions.

Conclusion

David McAllister's contributions to the field of pharmaceuticals, particularly through his innovative patent, demonstrate his dedication to improving healthcare solutions. His work continues to pave the way for advancements in the treatment of viral infections.